Private practice with Dr Seth Bilazarian

View all posts »

Forget about fish oil and multivitamins for secondary prevention of CV events

Nov 7, 2012 14:15 EST


There seems to be hope on the horizon for secondary prevention—as shown by promising results with colchicine and PCSK9 here in Los Angeles—but it's time to ditch your fish oil and multivitamins.

See also:

 








Your comments
Forget about fish oil and multivitamins for secondary prevention of CV events
# 1 of 4
November 8, 2012 09:34 (EST)
Larry Baruch
What was the colchicine dose in LoDoCo
# 2 of 4
November 10, 2012 12:00 (EST)
Bruce

If your intent here is to address patients rather than colleagues then you are making the mistake which it seems is becoming almost the rule with specialists: you confuse your specialty with medicine as a whole and make recommendations based upon your narrow little worldview of cardiology rather tahn upon what is helpful for the head-to-toe health of your patients and readers.

But it's one thing to be injudicious and another to be just plain medically reckless and you win the bonehead-of-the-month award for the latter in telling people, literally, to stop taking multivitamins. Geeze, I mean even if you don't do much reading outside your cardiology world, surely you read the daily paper, or Time Magazine or the Wall Street Journal. All of them and thousands more published in the last month the results of a double-blind study by Dr. J. Michael Gaziano, of Brigham and Women's Hospital of 15,000 male physicians, half of whom took placebo and half of whom took a multivitamin.

After 11 years, a statistically significant 8% reduction in the number of cancers was observed for the group taking multivitamins. Not an earthshaking number, but one which should shut up know-it-alls who, as it happens, don't quite know it all. If taking multivitamins can affect 1 disease process, how many others might it affect? Apparently, you're not interested in the answer.

Here's the link in a publication which you will want to afford great authority: http://www.usatoday.com/story/news/nation/2012/10/17/multivitamins-cancer-risk-men/1638929/.

# 3 of 4
November 12, 2012 07:58 (EST)
EddieVos
First, fish oil pills, the only sustainable way to get marine fatty acids.  As Dr. Seth B should well know, there was a highly significant p=0.009 benefit in late secondary prevention heart failure patients in the respected n=~7000 GISSI-HF trial [Lancet 2008, supported by Pfizer and AZ].   Not all trials are as well set up and designs differ, some set up for failure.  Low cost, no harm.

Second, vitamins.  HOPE-2, also well respected, found a stroke benefit in late secondary prevention while in stroke victims with [extremely high, likely stroke-causal, homocysteine] and thus a very high hip fracture risk, there was an 80% reduced risk thereof -vs- placebo from only 2 homocysteine lowering B-vitamins such as is found in a high level multivitamin.  Interestingly, there was likely improved collagen quality in those patients and we all know that collagen has a short half life in heart [~4 months] yet it being its main structural protein.  Copy and paste this for a combo-graph www.health-heart.org/HIPandHOPE.gif

Let's not flush OTC known essential nutrient supplements since there is plenty to be happy about.  For example, cost, safety -- if not the failure of statins to ever reduce mortality in women [all RCTs] and in anybody over age 70 [PROSPER] as well as the failure to lower mortality in all studies ever done using atorva, lova, ceriva and fluva-statin, and re CV mortality using rosuva.
# 4 of 4
November 12, 2012 03:32 (EST)
dave

the last comment was sponsored by GNC. makers of fine vitamans for all disseases


You must be a member (with full membership) to post a comment.
Already a member?
Enter your login information below:
 Remember me on this computer
Enjoy all the benefits of theheart.org

With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.

Membership is free!

About Dr Seth Bilazarian
Seth Bilazarian MD has been a Clinical and Interventional Cardiologist at Pentucket Medical Associates in Massachusetts since 1993. He is board certified in Internal Medicine, Cardiovascular Medicine, Nuclear Cardiology, Vascular Ultrasound, Interventional Cardiology, and Vascular and Endovascular Medicine.

Dr Bilazarian performs coronary and peripheral interventions at Lahey Clinic and Massachusetts General Hospital. He has been an investigator in the interventional laboratory for new devices including drug-eluting stents, distal protection devices, imaging devices (OCT and InfraRed), and anticoagulant pharmacotherapy.

Dr Bilazarian is an active participant in clinical trials in congestive heart failure, hypertension, coronary disease prevention, prediabetes management, anemia, atrial fibrillation, and anticoagulation/antiplatelet therapies in the outpatient setting. He has authored numerous papers and book chapters in clinical cardiology. He was appointed as a physician advisor to the circulatory device panel of the FDA in 2008.
About this blog
My intent is to create a forum for dialogue on issues pertinent to private practice cardiology around topics such as:

  • Integration of new data and guidelines on inpatient and outpatient practice in clinical and interventional cardiology
  • Practice approaches to the extra clinical issues in dealing with managed care insurers
  • Strategies for navigating the restrictions of pharmacy benefits managers (PBMs) on pharmacologic therapies for our patients
  • Experiences with restrictions on testing and imaging
The video blog (VLOG) will provide an opportunity to share broadly different approaches to the common conundrums we face in caring for patients. My hope is that this forum will provide useful data points for practice outside of tertiary and academic centers and a look inside community hospitals and physician?s practice patterns in the office, starting with mine.